Ovarian cancer is a most lethal gynecologic tumor. The mainstay treatment is cytoreductive surgery followed by platinumbased chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. In the last two decades, research has focused on the potential of target therapies to improve the survival of patients affected by ovarian cancer. Bevacizumab is one of the most studied target therapies, and it is approved for first- and second-line treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal tumors. Despite its widespread use with favorable results, controversy regarding patient selection and the best schedule, dosage, and timing of bevacizumab still exists. This review summarizes the state of the art on the use of bevacizumab for ovarian cancer in front-line, recurrence, and neoadjuvant settings. This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients.

Musella, A., Vertechy, L., Romito, A., Marchetti, C., Giannini, A., Sciuga, V., Bracchi, C., Tomao, F., Di Donato, V., De Felice, F., Monti, M., Muzii, L., Panici, P. B., Bevacizumab in ovarian cancer: State of the art and unanswered questions, <<CHEMOTHERAPY>>, 2017; 62 (2): 111-120. [doi:10.1159/000448942] [http://hdl.handle.net/10807/201318]

Bevacizumab in ovarian cancer: State of the art and unanswered questions

Marchetti, Claudia;
2016

Abstract

Ovarian cancer is a most lethal gynecologic tumor. The mainstay treatment is cytoreductive surgery followed by platinumbased chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. In the last two decades, research has focused on the potential of target therapies to improve the survival of patients affected by ovarian cancer. Bevacizumab is one of the most studied target therapies, and it is approved for first- and second-line treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal tumors. Despite its widespread use with favorable results, controversy regarding patient selection and the best schedule, dosage, and timing of bevacizumab still exists. This review summarizes the state of the art on the use of bevacizumab for ovarian cancer in front-line, recurrence, and neoadjuvant settings. This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients.
2016
Inglese
Musella, A., Vertechy, L., Romito, A., Marchetti, C., Giannini, A., Sciuga, V., Bracchi, C., Tomao, F., Di Donato, V., De Felice, F., Monti, M., Muzii, L., Panici, P. B., Bevacizumab in ovarian cancer: State of the art and unanswered questions, <<CHEMOTHERAPY>>, 2017; 62 (2): 111-120. [doi:10.1159/000448942] [http://hdl.handle.net/10807/201318]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/201318
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 29
social impact